Skip to main content
Enlivex Therapeutics Ltd. logo

Enlivex Therapeutics Ltd. — Investor Relations & Filings

Ticker · ENLV ISIN · IL0011319527 TA Manufacturing
Open in API
Filings indexed 485 across all filing types
Latest filing 2020-08-10 Regulatory Filings
Country IL Israel
Listing TA ENLV

About Enlivex Therapeutics Ltd.

https://enlivex.com/

Enlivex Therapeutics Ltd. is a clinical-stage macrophage reprogramming immunotherapy company. It is focused on developing Allocetra™, a universal, off-the-shelf cell therapy designed to treat immune system dysregulation. The therapy works by reprogramming macrophages to resolve hyper-inflammation. Enlivex is evaluating Allocetra™ in clinical trials for the treatment of multiple indications, including acute inflammatory diseases such as sepsis and chronic inflammatory conditions like osteoarthritis. The product candidate offers flexible administration options, including systemic intravenous infusion and targeted local injections.

Recent filings

Filing Released Lang Actions
Enlivex Announces Dosing of First Patient in Clinical Trial of Allocetra in COVID-19 Patients with Severe Illness Respiratory Failure
Regulatory Filings Classification · 1% confidence The document explicitly states it is a "Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934," which corresponds to a Form 6-K filing. Form 6-K filings are generally used by foreign private issuers to report material information to the SEC, often mirroring the function of a current report (8-K) in the US system. Since the provided definitions do not include a specific code for Form 6-K, and the content is a press release announcing a clinical trial update furnished as an exhibit to the 6-K, it falls under the category of general regulatory announcements that do not fit the more specific categories like ER (Earnings Release) or LTR (Legal Proceedings Report). Therefore, the most appropriate fallback category is Regulatory Filings (RNS). The document length (6266 chars) is substantial enough that it is the filing itself, not just an announcement of a filing, although the content is a press release attached to the 6-K.
2020-08-10 English
Enlivex Announces Dosing of First Patient in Clinical Trial of Allocetra in COVID-19 Patients with Severe Illness Respiratory Failure
Report Publication Announcement Classification · 1% confidence The document is extremely short (1754 characters) and explicitly states, "Attached hereto is a report on *6-K* *6K10082020_isa.pdf*". This structure indicates that the document itself is an announcement about the publication of another report (the 6-K filing), rather than the full content of the 6-K report. According to Rule 2, when a document is short and announces the availability of another report, it should be classified as a Report Publication Announcement (RPA). The filing is made to the Israel Securities Authority and Tel Aviv Stock Exchange, but the function of this specific text is to announce the release of the attached 6-K.
2020-08-10 English
Enlivex held its 2020 Annual and Extraordinary General Meeting of Shareholders
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is explicitly identified as a 'Form 6-K' filed by a Foreign Private Issuer (Enlivex Therapeutics Ltd.) with the SEC. The content details the results of the '2020 Annual and Extraordinary General Meeting of Shareholders' (the Meeting), including the approval of resolutions regarding director re-election, compensation policy, and auditor reappointment. Since the document reports the official results of shareholder voting from a general meeting, it aligns best with the 'Declaration of Voting Results & Voting Rights Announcements' category (DVA). Although it mentions the AGM, the core purpose of this specific 6-K filing is to report the *results* of the votes taken, not just general AGM information or a proxy statement.
2020-06-29 English
Enlivex held its 2020 Annual and Extraordinary General Meeting of Shareholders
Report Publication Announcement Classification · 1% confidence The document is extremely short (1757 characters) and explicitly states, "Attached hereto is a report on *6-K* *6k29062020_isa.pdf*". This structure indicates that the document itself is an announcement about the publication of another report (a Form 6-K, which is a general report for foreign private issuers, often used for material events). According to Rule 2, when a document is short and announces the attachment or publication of a report, it should be classified as a Report Publication Announcement (RPA). Since RPA is a specific category for this scenario, it takes precedence over the general fallback (RNS).
2020-06-29 English
Enlivex Announces Allowance of New Japanese Patent Application Covering ALLOCETRA Immunotherapy
Regulatory Filings Classification · 1% confidence The document is explicitly titled 'Form 6-K' and is filed with the 'UNITED STATES SECURITIES AND EXCHANGE COMMISSION'. Form 6-K is the standard filing for a 'Report of Foreign Private Issuer' under the Securities Exchange Act of 1934. The content is a press release announcing the allowance of a Japanese patent for their product ALLOCETRA, which is being furnished as Exhibit 99.1 to the Form 6-K. Since the Form 6-K itself is a regulatory filing used to report material information not otherwise covered by periodic reports (like 10-K or 20-F), and it doesn't fit the specific definitions for ER, IR, DIV, etc., it falls best under the general 'Regulatory Filings' category (RNS) or, given its nature as a specific SEC form, it might be considered a specialized regulatory document. However, looking at the provided codes, RNS is the most appropriate general regulatory filing fallback for non-standard SEC forms or general announcements. Since the document is a complete SEC filing (Form 6-K) containing material news, and RNS is defined as 'General regulatory announcements and fallback category for miscellaneous filings that do not neatly fit into other specific categories,' RNS is the best fit among the choices for a Form 6-K.
2020-06-18 English
Enlivex Announces Allowance of New Japanese Patent Application Covering ALLOCETRA Immunotherapy
Report Publication Announcement Classification · 1% confidence The document is very short (1757 characters) and explicitly states, "Attached hereto is a report on *6-k* *6k18062020_isa.pdf*". The presence of the SEC Form 6-K (which is an 'Other Report' for foreign private issuers) being announced, rather than the full content of the 6-K itself, strongly suggests this is an announcement about the filing. Since 6-K filings do not map directly to a specific category like 10-K or IR, and this document serves to announce the publication of an external report, the most appropriate classification based on the 'MENU VS MEAL' rule is Report Publication Announcement (RPA). If RPA were not available, RNS would be the fallback, but RPA fits the context of announcing a report release better.
2020-06-18 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.